X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs CIPLA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. CIPLA FRESENIUS KABI ONCO./
CIPLA
 
P/E (TTM) x 22.1 44.1 50.2% View Chart
P/BV x 3.1 3.6 85.7% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 FRESENIUS KABI ONCO.   CIPLA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
CIPLA
Mar-17
FRESENIUS KABI ONCO./
CIPLA
5-Yr Chart
Click to enlarge
High Rs176622 28.3%   
Low Rs79458 17.1%   
Sales per share (Unadj.) Rs37.7181.9 20.7%  
Earnings per share (Unadj.) Rs5.112.9 39.6%  
Cash flow per share (Unadj.) Rs6.729.3 22.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs42.5155.7 27.3%  
Shares outstanding (eoy) m158.23804.51 19.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.43.0 113.7%   
Avg P/E ratio x25.042.0 59.5%  
P/CF ratio (eoy) x18.918.4 102.7%  
Price / Book Value ratio x3.03.5 86.2%  
Dividend payout %015.5 0.0%   
Avg Mkt Cap Rs m20,135434,516 4.6%   
No. of employees `0001.223.0 5.0%   
Total wages/salary Rs m70326,338 2.7%   
Avg. sales/employee Rs Th5,176.26,349.1 81.5%   
Avg. wages/employee Rs Th610.41,143.0 53.4%   
Avg. net profit/employee Rs Th699.6449.3 155.7%   
INCOME DATA
Net Sales Rs m5,963146,302 4.1%  
Other income Rs m182,287 0.8%   
Total revenues Rs m5,981148,589 4.0%   
Gross profit Rs m1,43024,758 5.8%  
Depreciation Rs m25813,229 1.9%   
Interest Rs m-261,594 -1.6%   
Profit before tax Rs m1,21612,222 10.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3421,798 19.0%   
Profit after tax Rs m80610,354 7.8%  
Gross profit margin %24.016.9 141.7%  
Effective tax rate %28.114.7 191.3%   
Net profit margin %13.57.1 191.0%  
BALANCE SHEET DATA
Current assets Rs m5,10287,370 5.8%   
Current liabilities Rs m2,38533,081 7.2%   
Net working cap to sales %45.637.1 122.8%  
Current ratio x2.12.6 81.0%  
Inventory Days Days15087 172.5%  
Debtors Days Days11362 181.8%  
Net fixed assets Rs m5,148111,567 4.6%   
Share capital Rs m1581,609 9.8%   
"Free" reserves Rs m6,556123,645 5.3%   
Net worth Rs m6,732125,254 5.4%   
Long term debt Rs m95236,454 2.6%   
Total assets Rs m10,388209,532 5.0%  
Interest coverage x-45.88.7 -528.1%   
Debt to equity ratio x0.10.3 48.6%  
Sales to assets ratio x0.60.7 82.2%   
Return on assets %7.55.7 131.7%  
Return on equity %12.08.3 144.8%  
Return on capital %14.68.5 171.8%  
Exports to sales %74.534.2 217.7%   
Imports to sales %24.88.3 297.0%   
Exports (fob) Rs m4,44150,050 8.9%   
Imports (cif) Rs m1,47712,203 12.1%   
Fx inflow Rs m5,29851,066 10.4%   
Fx outflow Rs m1,77217,678 10.0%   
Net fx Rs m3,52533,388 10.6%   
CASH FLOW
From Operations Rs m1,27423,824 5.3%  
From Investments Rs m-1,204-13,127 9.2%  
From Financial Activity Rs m-196-13,239 1.5%  
Net Cashflow Rs m-126-2,478 5.1%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 81.0 20.8 389.4%  
Indian inst/Mut Fund % 0.3 12.2 2.5%  
FIIs % 9.6 23.7 40.5%  
ADR/GDR % 0.0 1.1 -  
Free float % 9.1 26.2 34.7%  
Shareholders   42,599 161,166 26.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   WYETH LTD  PFIZER  NATCO PHARMA  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS